标准桃金娘油治疗慢性支气管炎和COPD的系统评价

目的:系统评价标准桃金娘油治疗慢性支气管炎和慢性阻塞性肺疾病(COPD)的疗效及安全性。方法:计算机检索Co-chrane图书馆(2011年第3期)、EMbase、PubMed、中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、中文科技期刊全文数据库(VIP)关于标准桃金娘油治疗慢性支气管炎和COPD的随机对照试验(RCT)。对纳入研究的方法学质量进行评价,应用RevMan5.10软件对数据进行Meta分析。结果:共纳入15项RCT,包括1617名患者。Meta分析结果显示,与对照组比较,标准桃金娘油治疗慢性支气管炎和COPD能够显著提高治疗总有效率RR=1.24,95%CI(1.15,1.35),P<0.00001];改善血气分析,提高氧分压(PaO2)MD=7.55,95%CI(4.60,10.50),P<0.00001],降低二氧化碳分压(PaCO2)MD=-5.46,95%CI(-6.69,-4.24),P<0.00001];改善肺功能,提高每秒用力呼气容积(FEV1%)MD=7.27,95%C(I5.98,8.56),P<0.00001];改善临床症状体征;减少急性发作次数RR=0.58,95%C(I0.42,0.79),P<0.05],差异均有统计学意义。在不良反应发生率方面,与对照组比较差异无统计学意义。结论:标准桃金娘油治疗慢性支气管炎和COPD有效,安全性好。但由于纳入研究质量不统一,本结论尚需要更多大样本、高质量RCT予以证实。

Standard Myrtol in the Treatment of Chronic Bronchitis and COPD:A Systematic Review

OBJECTIVE:To evaluate the therapeutic efficacy and safety of standard myrtol in the treatment of chronic bronchitis and COPD.METHODS:We searched the Cochrane Library(issue 3,2011),EMbase,PubMed,CNKI,CBM and VIP for RCTs of standard Myrtol for chronic bronchitis and COPD.The methodological quality of included trials was evaluated,and Meta-analysis was performed by Rev Man 5.10 software.RESULTS:15 RCTs involving 1 617 patients were ultimately identified.The results of Meta-analysis showed that,compared with control group,standard Myrtol in the treatment of chronic bronchitis and COPD could improve total effective rates RR=1.24,95%CI(1.15,1.35),P<0.000 01] and blood gas analysis,increased PaO2 MD=7.55,95%CI(4.60,10.50),P<0.000 01],decreased PaCO2 MD=-5.46,95%CI(-6.69,-4.24),P<0.000 01],improved pulmonary function and increased FEV1% MD=7.27,95%CI(5.98,8.56),P<0.000 01],ameliorated clinical symptoms and reduced the frequency of exacerbation RR=0.58,95%CI(0.42,0.79),P<0.05].There was no statistical difference in the incidence of adverse drug reactions between 2 groups.CONCLUSIONS:Standard myrtol is effective and has good safety in the treatment of chronic bronchitis and COPD.However,due to the quality of included studies,more large-scale high-quality RCTs are needed.